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OBJECTIVES This study was designed to evaluate the efficacy of atenolol for the long-term management of
patients with vasovagal syncope. The primary hypothesis was that atenolol is not superior to
placebo for the treatment of vasovagal syncope.
BACKGROUND There is no definitive well-controlled analysis of the efficacy of beta-adrenergic blocking
agents in patients with recurrent vasovagal syncope.
METHODS This is a prospective, randomized, double-blind, placebo-controlled study. Fifty patients with
recurrent vasovagal syncope were included (at least two episodes in the last year). A baseline
tilt test was performed. Twenty patients (40%) had a positive tilt test. Intravenous atenolol
prevented a second positive tilt in five patients. The patients were randomized to receive
either atenolol or a placebo (26 patients atenolol 50 mg/day, 24 patients placebo). The
follow-up procedure lasted one year. The primary end point of the study was the time to first
recurrence of syncope.
RESULTS In the intention-to-treat analysis, the group treated with atenolol had a similar number of
patients with recurrent syncopal episodes as the placebo group. The Kaplan-Meier actuarial
estimates of time to first syncopal recurrence showed that the probability of remaining free of
syncope drops similarly in both groups and that there was no statistical difference between
both curves (patients treated with atenolol vs. the placebo) with a log-rank test p value of
0.4517.
CONCLUSIONS The recurrence of neurocardiogenic syncope in highly symptomatic patients treated with
atenolol is similar to that of patients treated with placebo. (J Am Coll Cardiol 2001;37:
554–9) © 2001 by the American College of Cardiology
The optimal approach to the treatment of patients with
neurocardiogenic syncope remains uncertain (1,2). Many
types of treatment have been proposed that are based largely
on small nonrandomized studies and clinical series. There is
a remarkable absence of data from randomized and prospec-
tive clinical trials (3–14). The triggering event for an episode
of vasovagal syncope is thought to be an increase in
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adrenergic tone resulting in the activation of cardiac mech-
anoreceptors. Beta-adrenergic blocking agents would act by
inhibiting the activation of the left ventricular mechanore-
ceptors because of their beta-blocking, blocking the initial
increase in adrenergic tone and negative inotropic effects.
There are, however, few well-controlled analyses on the
efficacy of beta-blockers (15–21). Thus, we began this study
in an attempt to establish the efficacy of atenolol in the
treatment of vasovagal syncope.
METHODS
Patients. We included 50 patients in this study. They were
recruited consecutively from patients referred to our ar-
rhythmia unit. All the patients had a clinical history
consistent with the diagnosis of recurrent vasovagal syncope.
Substantiation of the diagnosis was based on their clinical
histories: a transient loss of consciousness with the typical
precipitating factors (triggers: prolonged standing, pain, the
sight of blood, a warm environment or hot shower and
stressful situations) and prodromal symptoms (palpitations,
severe light-headedness associated with nausea and dia-
phoresis). The inclusion criteria were: age 18 to 75 years
with at least two syncopal events during the previous year. A
complete study (physical examination, 24-h ambulatory
electrocardiogram, echocardiography, bilateral carotid sinus
massage, routine hematological and biochemical investiga-
tions, 12-lead surface electrocardiogram and chest X-ray)
was performed to eliminate other possible causes of syncope
in all patients during the inclusion phase. Potential arrhyth-
mic causes of these syncopal episodes were excluded based
on the absence of structural heart disease and arrhythmic
events during 24-h Holter monitoring or clinical data that
could suggest an underlying arrhythmia. Exclusion criteria
were: 1) pregnancy or lactation; 2) the presence of another
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possible etiology for syncope; 3) severe peripheral arterial
disease, diabetes mellitus, atrioventricular conduction dis-
turbances (intraventricular conduction defects or an abnor-
mal PR interval) or documented autonomic dysfunction
(chronically impaired sympathetic efferent activity so that
vasoconstriction is deficient; upon standing, blood pressure
always falls, i.e., orthostatic hypotension, defined as a
decrease of at least 15 mm Hg); 4) hypersensitivity or any
other contraindication for beta-blocker therapy; 5) neoplas-
tic or psychiatric diseases; 6) drug addiction or any other
medical condition that, in the opinion of the investigators,
could make the patient inappropriate for the study.
Clinical data. The mean age of the patients was 31 6 10
years; 30 were female, and 20 were men. The mean duration
of symptoms was 65 6 57 months. The median number of
syncopal events per patient during the year before the
inclusion in the study was three. All the patients had a blood
pressure and heart rate within normal limits: systolic mean
blood pressure: 121 6 3 mm Hg, diastolic: 71 6 2 mm Hg,
mean heart rate 67 6 2 beats/min. The results of the tests
performed during the inclusion phase were normal in all
patients.
Study design and end points. This is a prospective, ran-
domized, double-blind and placebo-controlled study on the
efficacy of atenolol versus placebo for the treatment of
recurrent vasovagal syncope in a general population with a
high number of syncopal episodes. The primary hypothesis
was that atenolol is not superior to a placebo for the
treatment of vasovagal syncope. The study protocol was
approved by the ethics committee of the hospital. Written
informed consent was obtained from each patient.
During the first visit all patients underwent a tilt-table
test. In the patients with a positive response, a second tilt
test with intravenous atenolol was performed. The patients
were then randomized to receive oral atenolol (50-mg pills)
or a placebo—one pill every day (regardless of the result of
the tilt test). The pills were identical in shape, color and
size. The patients were then followed up for one year.
Examinations were performed every two months. At each
examination, an accurate history, a physical examination
and an electrocardiogram were performed. The clinical
recurrences of the syncope and possible adverse effects were
evaluated. In the case of recurrences, the drug could be
increased to 100 mg daily if tolerated. In the case of adverse
effects or intolerance, the dose could be decreased to 25 mg
daily. The boxes were returned after each visit. Drug
compliance was assessed by pill counting.
Criteria for withdrawal from the study included the
patient’s refusal to continue, noncompliance, protocol vio-
lation or serious adverse events. Patients who dropped out
because of intolerable adverse effects of the drug or because
they had no therapeutic response with severe symptoms
were considered completed cases for the intention-to-treat
analysis. The code was not broken until the end of the study.
The main objective of this study was to evaluate the
efficacy of oral atenolol to prevent recurrences of vasovagal
syncope in a highly symptomatic population. The primary
end point of the study was the time to first recurrence of
syncope.
Tilt-test protocol and definitions. The patient was placed
in a supine position on a motorized tilt table with footboard
support. An intravenous catheter was placed in an arm vein
for an infusion of 5% glucose solution and the administra-
tion of emergency medications, if necessary. Continuous
electrocardiographic monitoring was recorded, and nonin-
vasive automated blood pressure monitoring was performed
(Finapress digital photoplethysmography: Ohmeda, Madi-
son, Wisconsin). Blood pressure and heart rate were con-
tinuously recorded. After a 10-min supine control phase, the
patients were tilted upright to an angle of 80° for 45 min or
until a positive response was achieved. A positive response
was defined as: 1) reproduction of the symptoms that had
been associated with the patient’s clinical events or 2) a
sudden loss of consciousness or the development of presyn-
cope in association with an abrupt decrease in systolic blood
pressure of 30 mm Hg or 20% to 30% of previous values.
We considered three types of syncope according to the
changes in heart rate and blood pressure detected during the
episodes: 1) vasodepressor, with an abrupt decrease of
systolic blood pressure over 30 mm Hg (or 20% to 30% of
the basal value); 2) cardioinhibitory, with a decrease in heart
rate over 20% of the measurement taken immediately before
the episode and 3) a mixed response, with both bradycardia
and hypotension.
If a positive response occurred during the upright tilt,
patients were returned to the supine position, and the test
was terminated. All the patients with a positive test under-
went an infusion of intravenous atenolol (3 h after the first
tilt test). The dose of atenolol varied from 5 to 10 mg
depending on a heart rate higher than 50 beats/min and
blood pressure, with a decrement ,25% over baseline. A
second tilt test was then performed following the same
protocol.
Sample size calculation. The sample size calculation was
based on an estimated efficacy of 70% for atenolol and 25%
for the placebo, with an alpha level of 0.05 and a test power
of 0.80. The resulting sample size was 23 patients for each
treatment group. Most of the published reviews of the
treatment of vasovagal syncope advise the use of beta-
blockers for the treatment of vasovagal syncope. Moreover,
it is well known that these patients could improve even
without any specific treatment, after counseling. We took
these percentages as an estimation from the published data
(22,23).
Statistical analysis. The primary analysis of the results of
the study was by intention-to-treat analysis. The time to
first syncopal recurrence was analyzed using the Kaplan-
Meier curves and compared using the log-rank test. Hazard
ratio and its confidence intervals were estimated using the
Cox regression model. The statistical package used was
SPSS 9.0 for Windows. Means (6 standard deviation) and
medians were calculated for continuous variables, and fre-
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quencies were measured for categorical variables. Differ-
ences between groups were examined for statistical signifi-
cance by a Student t test for continuous variables, with the
Mann-Whitney U test for the variables nonparametrically
distributed and by Fisher exact test for categorical variables.
A p value ,0.05 was considered significant.
RESULTS
About 700 patients with unexplained syncope were referred
to us for evaluation in our arrhythmia unit. About 300 of
these (43%) had a clinical history consistent with vasovagal
syncope. Two hundred thirty patients were ineligible for the
study due to: only one syncopal episode during the previous
year (148 patients), age , 18 years (53 patients), age . 75
years (12 patients), diabetes mellitus (14 patients), organic
heart disease (36 patients), abnormal electrocardiogram (27
patients), possible pregnancy (6 patients), psychiatric disease
(4 patients) and another 18 patients who had more than one
reason. Seventy patients met the inclusion criteria. Of these,
50 gave their informed consent to take part in the study; 26
were randomly assigned to the atenolol arm and 24 to the
placebo arm. The patients were followed up for one year,
independently of the recurrence of syncopal episodes. Forty
patients completed the protocol of the study, and 10
patients discontinued the study. The compliance of the
patients that remained in the study was 100%.
Clinical data. The clinical characteristics of the patients
included in the study are summarized in Table 1. The
median number of syncopal events per patient during the
year prior to the inclusion in the study was three in patients
treated with atenolol, with no difference in comparison with
patients treated with placebo, who also had a median
number of syncopal events of three.
Head-up tilt test. With the tilt test, twenty patients (40%)
showed a positive response, whereas 30 showed no change
during the tilt test. The group with a negative tilt test result
was made up of: 30 patients, with a mean age of 35 6 10
years, 19 female, mean duration of symptoms 65 6 59
months; 18 of these patients were treated with atenolol and
12 with placebo. The group with a positive result from the
initial tilt test was made up of: 20 patients, with a mean age
of 27 6 8 years, 11 female, mean duration of symptoms
65 6 55 months; 8 were treated with atenolol and 12 with
placebo. There were no significant differences between the
two groups (patients with a positive versus negative tilt test)
with respect to age, gender, blood pressure, heart rate and
number of syncopal events. In tilt positive patients, six had
a vasodepressor response, five a predominant cardioinhibi-
tory response and nine a mixed response. Eighteen of the 20
patients who had a positive response received intravenous
atenolol before a second tilt test was performed. Atenolol
prevented a second positive response in only five patients
(25%). In patients with a predominant cardioinhibitory
response (five patients), atenolol did not prevent a second
positive response in any of them.
Efficacy during long-term treatment. The median num-
ber of syncopal events during the follow-up procedure was
two for those patients treated with atenolol and 0 for those
patients treated with placebo (p 5 0.215). This difference
was not statistically significant although it appears that the
recurrence rate of syncope drops in both groups, simply after
tilt-table testing. In the intention-to-treat analysis, the
group treated with atenolol had a similar number of patients
with recurrent syncopal events as the placebo group (16 and
11 patients, 61.5% and 45.8%, respectively, in each group,
p 5 0.09). The median time to the first recurrence of a
syncopal event for all the patients was seven months, with a
standard error of 3.77 and 95% confidence interval between
0 to 14.39 months. The Kaplan-Meier actuarial estimates of
first syncopal recurrence showed that the probability of
remaining free of syncopal events drops similarly in both
groups. There was no statistical difference between both
curves (patients treated with atenolol vs. the placebo), with
a p value of 0.4517 (Fig. 1). Atenolol was associated with a
38% increase in the rate of recurrent syncope, relative risk
1.38 (0.64 to 3.01), but there was no difference in these two
groups (atenolol or placebo) given that the confidence
intervals are extremely wide (p 5 0.405).
Data were analyzed depending on the outcome of tilt-
table testing. To find out the possible difference in the
Figure 1. Primary hypothesis of the study. Kaplan-Meier estimates of the
probability of remaining free of syncopal recurrence (time to first syncopal
recurrence) in the patients treated with atenolol or the placebo. Dotted
line 5 atenolol; solid line 5 placebo.
Table 1. Baseline Clinical Data of Patients
Atenolol
n 5 26
Patients
Placebo
n 5 24
Patients p Value
Mean (6SD) age, yrs 32 6 12 31 6 8 0.37
Men/women 11/15 9/15 0.50
Mean duration of symptoms
before the study (months)
68 6 50 61 6 64 0.37
Median number of syncopes
per patient
3 3 0.215
Supine systolic arterial blood
pressure, mm Hg
118 6 12 120 6 12 0.34
Supine diastolic arterial
blood pressure, mm Hg
70 6 7 73 6 6 0.13
Heart rate, beats/min 68 6 5 70 6 8 0.19
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natural history of patients according to the result of the tilt
test, we compared the outcome of patients with a positive or
negative tilt-table test result in the placebo group. A positive
tilt-table test was associated with an increased risk of
recurrent syncope: relative risk 3.39 (0.89 to 12.95). How-
ever, it did not reach statistical significance (p 5 0.0582).
The probability of syncope-free survival was analyzed using
the Kaplan-Meier curves comparing patients with negative
tilt test treated with atenolol and patients treated with the
placebo. These were not statistically different, p 5 0.0744,
although there seemed to be a trend towards a better
outcome for patients treated with placebo. The Kaplan-
Meier curves (probability of syncope-free survival) between
patients with positive tilt test treated with atenolol and
patients with the placebo were not statistically different, p 5
0.6184 (Fig. 2).
Adverse events. A total of five adverse events were regis-
tered: four in patients treated with atenolol and one occur-
ring in the placebo group (p , 0.05). Four of them were
judged as being possibly related to the treatment. Fatigue,
bradycardia and headache were observed in three patients
treated with atenolol, and alterations of the libido were
observed in one patient treated with placebo. No deaths or
serious syncopal event-associated traumas occurred during
the study.
DISCUSSION
Therapy of vasovagal syncope. Syncope is one of the most
common clinical problems in medical practice. The treat-
ment of patients with vasovagal syncope is still a subject of
controversy. This controversy exists for several reasons: 1)
the natural history of vasovagal syncope is still not well
known, with a clustering behavior and long periods without
any symptoms; 2) there is a lack of consensus, and both
randomized and controlled studies are needed. Many drugs
have been used for this purpose (disopyramide, transdermal
scopolamine, fludrocortisone, etilefrine, beta-blockers, etc.)
(3–14). None of the drugs has been unequivocally proven
for long-term effectiveness, based on adequate randomized
controlled clinical trials. The frequency of syncopal events
decreases significantly in patients with vasovagal syncope
during follow-up procedures after a positive response in a
head-up tilt test, even with no specific treatment. However,
this could be due both to the role that the tilt test plays in
the treatment of these patients and the medical advice.
Several studies have demonstrated no significant effect of
drugs in preventing vasovagal syncope, such as disopyramide
(3), scopolamine (4) and etilefrine (VASIS) (6). Midodrine
has been used with better results (8,9). With regard to
placebo control, a few trials have demonstrated benefits
(8,17,24,25). Pacing may be a therapeutic alternative for
some patients with recurrent vasovagal syncope although
more randomized controlled studies are needed (10,11,26).
Role of tilt-table testing. There is a general consensus that
tilt-table testing is an important diagnostic tool in the
evaluation of patients with unexplained syncope, with a
good sensitivity (27,28) or specificity (29–32) in the absence
of high doses of isoproterenol. The clinical history should
continue to be the “gold standard” for the diagnosis of
vasovagal syncope, and, for this reason in our study, patients
with both positive and negative tilts were followed up.
Furthermore, a positive tilt table test may be associated with
a higher rate of recurrent syncope, and our data show that a
positive tilt (for placebo patients only) was associated with
an increased risk of having recurrent syncope, relative risk
3.39 (0.89 to 12.95), p 5 0.058. The value of the head-up
tilt test to qualify drugs for use in vasovagal syncope or for
predicting treatment efficacy is less certain. The therapeutic
value of serial tilting has been recognized (33). The barore-
ceptor response may be conditioned by serial tilt-table tests.
This remedy can be combined easily with the general
recommendations.
Beta-adrenergic receptor blocking drugs. Beta-blockers
have been widely used in the treatment of patients with
neurocardiogenic syncope, and they are frequently chosen as
a first line drug therapy. They were proposed more than a
Figure 2. Analyses of the data stratified by the outcome of tilt-table testing. Kaplan-Meier curves for the patients with tilt positive and tilt negative results,
time to first syncopal recurrence in the patients treated with atenolol or the placebo. Dotted line 5 atenolol; solid line 5 placebo.
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decade ago for use in preventing recurrent episodes of
vasodepressor syncope (34). These agents presumably exert
their effects by diminishing the degree of cardiac mechano-
receptor stimulation or by blocking the effects of high levels
of circulating catecholamines. Metoprolol, pindolol and
atenolol have been the most frequently studied beta-
blockers in vasovagal syncope. But, from an evidence-based
medicine point of view, the data that support this assertion
are dubious. As far as we know, the only randomized,
double-blind, placebo-controlled trial to evaluate the effi-
cacy of oral beta-blockers in the treatment of neurocardio-
genic syncope is the one performed by Mahanonda et al.
(17). They compared the efficacy of a beta-blocker (atenolol)
with a placebo in patients who had at least one episode of
syncope or two episodes of presyncope one month before
presentation. They randomized patients into an atenolol or
placebo group. The response rate (negativization of tilt-
table test) after one month of treatment was 62% versus 5%
(p 5 0.0004) in the atenolol and control groups, respec-
tively. Patients who received atenolol reported feeling better
compared with those who received placebo (71% vs. 29%,
p 5 0.02). The main limitation of the study was the short
follow-up period (only one month), bearing in mind that we
are dealing with patients with a disease (neurocardiogenic
syncope) with an unknown natural history. Patients who
have had many syncopal events in one month, for example,
may remain asymptomatic for long periods of time. In
addition, studies that evaluate drug efficacy in the treatment
of such a disease should have a longer follow-up period.
There are other studies that have evaluated the efficacy of
beta-blockers. Not all of them are randomized or placebo-
controlled studies. Sheldon et al. (15) studied the effects of
beta-blockers on the time to first syncope recurrence in a
controlled parallel, but not randomized, study. Syncope
recurred in 17 of the 52 patients who received beta-blockers
and in 28 of the 101 patients who were untreated. They
concluded that the treatment with these drugs had no
significant effect on preventing syncope recurrence. Cox et
al. (16) prospectively evaluated the efficacy of propranolol
(both intravenous during head-up tilt testing and oral in the
long-term) for preventing neurocardiogenic syncope. Oral
beta-blockers were effective by tilt-test criteria in 94% of the
patients, and 10% had recurrent clinical symptoms while
taking beta-blockers (atenolol, propranolol, metoprolol and
nadolol). Their conclusion was that intravenous propranolol
was very effective in blocking the abnormal neurocardio-
genic reflex during tilt testing and that it could predict a
good response to oral beta-blockers. This study was not
placebo-controlled, and the type of beta-blocker therapy
was not randomized. Natale et al. (12) published a report on
the treatment of 303 patients with a history of syncope
together with a positive head-up tilt. The recurrence of
symptoms was very low in this study, 12 of the 210 patients
treated according to the response to repeat head-up tilt, 130
of which were on metoprolol. This study was a retrospective
analysis and was neither randomized nor controlled.
In our study, we evaluated the efficacy of a beta-blocker,
atenolol, compared with a placebo in preventing recurrences
in patients with clinically diagnosed vasovagal syncope. The
end point was the time to first recurrence of syncope.
Intravenous atenolol was not an efficient drug in preventing
a second positive tilt test (only 25% of the patients). The
positive response to intravenous atenolol could not even
predict a good response to chronic oral administration. The
patients included in our study were highly symptomatic and
had more syncopal episodes before participating than the
patients in some of the other studies, which probably
accounts for the high recurrence rate in this study. After one
year of follow-up, there were no statistical differences
between patients treated with atenolol and patients treated
with the placebo. There are several main contributions of
our study. As far as we know, this is the first double-blind,
randomized, placebo-controlled trial on the efficacy of
beta-blockers for the treatment of neurally mediated syn-
cope with a long-term follow-up (one year). The benign
course of neurocardiogenic syncope may give the false
impression of drug (or pacemaker) efficacy. Randomized
controlled studies are essential to the assessment of the real
usefulness of any proposed therapy for patients with vaso-
vagal syncope (1,2).
Study limitations. There is not a “gold standard” method
for diagnosing vasovagal syncope. This fact will always be
difficult in the management of this important and frequent
clinical entity. Some of our patients could, in fact, have
another diagnosis although is very improbable because of
the consistent clinical history and the lack of new diagnosis
during the follow-up. In any case, this is a highly symp-
tomatic population, in which we feel that there is a necessity
to treat and to find out the results of any implemented
treatment. The relatively small number of patients included
makes it difficult to arrive at any firm conclusions to many
secondary aspects of our study. We did not use the tilt test
to select a specific population of vasovagal syncope. We
believe that a comprehensive clinical history remains the
best method for diagnosing vasovagal syncope. The
follow-up time of one year may seem to be rather short
because the long-term outcome for patients with vasovagal
syncope is not well established. However, even with a longer
follow-up period for our patients, we do not think that the
results would have been different, due to the trend shown by
the Kaplan-Meier curves.
The power of our study is 80%; with these initial data, the
chances that our study was erroneously negative (the type II
error) is 20%. However, from our data, the treatment of
these patients showed a lack of efficacy of atenolol, which
could even be worse than the placebo in some patients, and
it would be unethical to continue the study. It has been
estimated that, even with a greater number of patients, it
would have been impossible to show any significant differ-
ence between atenolol and placebo.
Conclusions. The main result of this study is that the
recurrence of vasovagal syncope in highly symptomatic
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patients treated with atenolol is similar to that of those
treated with a placebo. The result of the head-up tilt test
was not useful in predicting the response to the drug. This
study reinforces the necessity for randomized, prospective
and placebo-controlled trials to evaluate the benefit of any
therapy for patients with neurocardiogenic syncope.
Acknowledgments
The authors thank Dr. Victor Abraira, from the Biomedical
Statistic Unit, and Angeles Mejı´a, a nurse from the Ar-
rhythmia Unit, Ramo´n y Cajal Hospital, for their assistance.
Reprint requests and correspondence: Concepcio´n Moro,
Unidad de Arritmias, Hospital Ramo´n y Cajal, Carretera
Colmenar Viejo Km. 9,100, 28034 Madrid, Spain. E-mail:
cmoro@hrc.insalud.es.
REFERENCES
1. Benditt DG, Fahy GJ, Lurie KG, Sakaguchi S, Fabian W, Samniah
N. Pharmacotherapy of neurally mediated syncope. Circulation 1999;
100:1242–8.
2. Atiga W, Rowe P, Calkins H. Management of vasovagal syncope.
J Cardiovasc Electrophysiol 1999;10:874–86.
3. Morillo CA, Leitch JW, Yee R, Klein GJ. A placebo-controlled trial
of intravenous oral disopyramide for prevention of neurally mediated
syncope induced by head-up tilt. J Am Coll Cardiol 1993;22:1843–8.
4. Lee TM, Su SF, Chen MF, Liau CS, Lee YT. Usefulness of
transdermal scopolamine for vasovagal syncope. Am J Cardiol 1996;
78:480–2.
5. Moya A, Permanyer-Miralda G, Sagrista-Sauleda J, et al. Limitations
of head-up tilt test for evaluating the efficacy of therapeutic interven-
tions in patients with vasovagal syncope: results of a controlled study of
etilefrine versus placebo. J Am Coll Cardiol 1995;25:65–9.
6. Raviele A, Brignole M, Sutton R, et al. Effect of etilefrine in
preventing syncopal recurrence in patients with vasovagal syncope: a
double-blind, randomized, placebo-controlled trial. The Vasovagal
Syncope International study. Circulation 1999;99:1452–7.
7. Nelson SD, Stanley M, Love CJ, Coyne KS, Schaal SF. The
autonomic and hemodynamic effects of oral theophylline in patients
with vasodepressor syncope. Arch Intern Med 1991;151:2425–9.
8. Ward CR, Gray JC, Gilroy JJ, Kenny RA. Midodrine: a role in the
management of neurocardiogenic syncope. Heart 1998;79:45–9.
9. Mitro P, Trejbal D, Ryba´r R. Midodrine hydrochloride in the
treatment of vasovagal syncope. Pacing Clin Electrophysiol 1999;22:
1620–4.
10. Connolly SJ, Sheldon R, Roberts RS, Gent M. The North American
Vasovagal Pacemaker study (VPS). A randomized trial of permanent
cardiac pacing for the prevention of vasovagal syncope. J Am Coll
Cardiol 1999;33:16–20.
11. Brignole M, Rinuti O, Sutton R, et al. Dual-chamber pacing is
efficacious in treatment of neurally-mediated tilt positive cardioinhib-
itory syncope; pacemaker versus no therapy: a multicenter randomized
study. Circulation 1999;100:3387.
12. Natale A, Sra J, Dhala A, et al. Efficacy of different treatment
strategies for neurocardiogenic syncope. Pacing Clin Electrophysiol
1995;18:655–62.
13. Fitzpatrick AP, Ahmed R, Williams S, Sutton R. A randomized trial
of medical therapy in “malignant vasovagal syndrome or neurally-
mediated bradycardia/hypotension syndrome.” Eur J Cardiac Pacing
Electrophysiol 1991;2:99–102.
14. Brignole M, Menozzi C, Gianfranchi L, Lolli G, Bottoni N, Oddone
D. A controlled trial of acute and long-term medical therapy in
tilt-induced neurally mediated syncope. Am J Cardiol 1992;70:339–
42.
15. Sheldon R, Rose S, Flanagan P, et al. Effect of beta-blockers on the
time to first syncope recurrence in patients after a positive isoproter-
enol tilt-table test. Am J Cardiol 1996;78:536–9.
16. Cox MM, Perlman BA, Mayor MR, et al. Acute and long-term
beta-adrenergic blockade for patients with neurocardiogenic syncope.
J Am Coll Cardiol 1995;26:1293–8.
17. Mahanonda N, Kiertijai B, Kangkagate C, et al. Randomized double-
blind, placebo-controlled trial of oral atenolol in patients with unex-
plained syncope and positive upright tilt-table test results. Am Heart J
1995;130:1250–3.
18. Sra JS, Murthy VS, Jazayeri MR, et al. Use of intravenous esmolol to
predict efficacy of beta-adrenergic blocker therapy in patients with
neurocardiogenic syncope. J Am Coll Cardiol 1992;19:402–8.
19. Muller G, Deal BJ, Strassburger JF, et al. Usefulness of metoprolol for
unexplained syncope and positive response to tilt testing in young
persons. Am J Cardiol 1993;71:592–5.
20. Abe H, Kobayashi H, Nakashima Y, et al. Effects of beta-adrenergic
blockade on vasodepressor reaction in patients with vasodepressor
syncope. Am Heart J 1994;128:911–8.
21. Jhamb DK, Singh B, Sharda BM, et al. Comparative study of the
efficacy of metoprolol and verapamil in patients with syncope and
positive head-up tilt-test response. Am Heart J 1996;132:608–11.
22. Sheldon R, Rose S, Flanagan P, et al. Risk factors for syncope
recurrence after a positive tilt-table test in patients with syncope.
Circulation 1996;93:973–81.
23. Natale A, Geiger MJ, Maglio C, et al. Recurrence of neurocardiogenic
syncope without pharmacologic interventions. Am J Cardiol 1996;77:
1001–3.
24. Zeng C, Zhu Z, Liu G, et al. Randomized, double-blind, placebo-
controlled trial of oral enalapril in patients with neurally mediated
syncope. Am Heart J 1998;136:852–8.
25. Di Girolamo E, Di Iorio C, Sabatini P, et al. Effects of paroxetine
hydrochloride, a selective serotonin reuptake inhibitor, on refractory
vasovagal syncope: a randomized, double-blind, placebo-controlled
study. J Am Coll Cardiol 1999;33:1227–30.
26. Cheitlin M, Conill A, Epstein A, et al. ACC/AHA guidelines for
implantation of cardiac pacemakers and antiarrhythmia devices. J Am
Coll Cardiol 1998;31:1175–209.
27. Waxman M, Yao L, Cameron DA, et al. Isoproterenol induction of
vasodepressor-type reaction in vasodepressor-prone persons. Am J
Cardiol 1989;63:58–65.
28. Sumiyoshi M, Nakata Y, Mineda Y, et al. Response to head-up tilt
testing in patients with situational syncope. Am J Cardiol 1998;82:
1117–8.
29. Kapoor WN, Brant N. Evaluation of syncope by upright tilt testing
with isoproterenol: a nonspecific test. Ann Int Med 1992;116:358–66.
30. Shen WK, Jahangir A, Beinborn D, et al. Utility of a single-stage
isoproterenol tilt-table test in adults: a randomized comparison with
passive head-up tilt. J Am Coll Cardiol 1999;33:985–90.
31. Morillo CA, Klein GJ, Zandri S, Yee R. Diagnostic accuracy of a
low-dose isoproterenol head-up tilt protocol. Am Heart J 1995;129:
901–6.
32. Natale A, Akhtar M, Jazayeri M, et al. Provocation of hypotension
during head-up tilt testing in subjects with no history of syncope or
presyncope. Circulation 1995;92:54–8.
33. Di-Girolamo E, Di-Torio C, Leonzio L, et al. Usefulness of a tilt
training program for the prevention of refractory neurocardiogenic
syncope in adolescents: a controlled study. Circulation 1999;100:
1798–801.
34. Almquist A, Goldenberg I, Milstein S, et al. Provocation of brady-
cardia and hypotension by isoproterenol and upright posture in
patients with unexplained syncope. N Engl J Med 1989;320:346–51.
559JACC Vol. 37, No. 2, 2001 Madrid et al.
February 2001:554–9 Efficacy of Atenolol for the Management of Vasovagal Syncope
